Forte Biosciences (FBRX) Profit After Tax (2016 - 2026)

Forte Biosciences (FBRX) has 11 years of Profit After Tax data on file, last reported at -$22.1 million in Q1 2026.

• On a quarterly basis, Profit After Tax fell 41.39% year-over-year to -$22.1 million in Q1 2026; TTM through Mar 2026 was -$75.8 million, a 73.5% decrease from a year earlier, with the FY2025 full-year figure at -$69.4 million, down 95.54% from the prior year.
• Profit After Tax for Q1 2026 stood at -$22.1 million, up from -$24.8 million in the prior quarter.
• Over the last five years, Profit After Tax for FBRX reached as high as -$2.6 million in Q1 2022 and fell as low as -$24.8 million in Q4 2025.
• Historically, Profit After Tax has averaged -$10.1 million across 5 years, with a median of -$8.4 million in 2024.
• Across the five-year window, Profit After Tax jumped 56.13% in 2022 and tumbled 246.35% in 2025, its largest moves.
• Year by year, Profit After Tax stood at -$4.9 million in 2022, then declined by 20.4% to -$5.9 million in 2023, then dropped by 21.8% to -$7.2 million in 2024, then tumbled by 246.35% to -$24.8 million in 2025, then advanced by 10.64% to -$22.1 million in 2026.
• Per Business Quant data, the three most recent Profit After Tax figures were -$22.1 million in Q1 2026, -$24.8 million in Q4 2025, and -$17.7 million in Q3 2025.